This inventor holds 3 USPTO granted patents and 19 published patent applications, plus 4 CIPO patents and 6 EPO patents. Top assignees: Novartis Ag, Mitsubishi Pharma Corporation. Active years: 2012-2016.
Company Filing History:
3 out of 3,973 
1 out of 73 Years Active: 2012-2016
Title: Colleen Ruegger: Innovator in Sphingosine 1 Phosphate Receptor Modulators
Introduction
Colleen Ruegger is a prominent inventor based in Morris Plains, NJ (US). She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compositions involving sphingosine 1 phosphate (S1P) receptor modulators. With a total of 3 patents to her name, Ruegger's work has the potential to impact various therapeutic areas.
Latest Patents
Colleen Ruegger's latest patents focus on processes for creating stable compositions that include sphingosine 1 phosphate (S1P) receptor modulators. These inventions are designed to be suitable for use as dosage forms. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives. Ruegger's innovative approach aims to enhance the stability and efficacy of these compositions.
Career Highlights
Throughout her career, Colleen Ruegger has worked with notable companies in the pharmaceutical industry, including Novartis AG and Mitsubishi Pharma Corporation. Her experience in these organizations has allowed her to develop her expertise in drug formulation and innovation.
Collaborations
Colleen Ruegger has collaborated with esteemed colleagues such as Tomoyuki Oomura and Madhusudhan Pudipeddi. These partnerships have contributed to her success in advancing her research and patent applications.
Conclusion
Colleen Ruegger is a distinguished inventor whose work in sphingosine 1 phosphate receptor modulators showcases her commitment to innovation in the pharmaceutical field. Her contributions are poised to make a lasting impact on drug development and therapeutic applications.